On May 12, 2025, HC Wainwright & Co. analyst Andrew Fein released a report on Avidity Biosciences (RNA, Financial). The report maintains a 'Buy' rating for RNA, reflecting continued confidence in the company's performance and future prospects.
Despite maintaining the 'Buy' rating, HC Wainwright & Co. has lowered the price target for Avidity Biosciences (RNA, Financial) from $72.00 to $68.00. This adjustment represents a 5.56% decrease in the price target, indicating revised expectations amidst changing market conditions.
The current price target of $68.00 remains a positive outlook for Avidity Biosciences (RNA, Financial), suggesting that there is still potential growth anticipated for the stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for Avidity Biosciences Inc (RNA, Financial) is $66.85 with a high estimate of $96.00 and a low estimate of $48.00. The average target implies an upside of 139.85% from the current price of $27.87. More detailed estimate data can be found on the Avidity Biosciences Inc (RNA) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, Avidity Biosciences Inc's (RNA, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Avidity Biosciences Inc (RNA, Financial) in one year is $7.56, suggesting a downside of 72.87% from the current price of $27.87. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Avidity Biosciences Inc (RNA) Summary page.
